Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)
Information source: Takeda
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pharmacokinetics
Intervention: Colchicine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Takeda Official(s) and/or principal investigator(s): Matthew Davis, MD, Study Chair, Affiliation: Mutual Pharmaceutical Company, Inc. Javier T Quesada, DO, Principal Investigator, Affiliation: West Coast Clinical Trials, LLC
Summary
The primary objective of this study is to compare the pharmacokinetic profiles of colchicine
and its primary metabolites in plasma and urine following a single 0. 6 mg oral dose of
colchicine in healthy adults with normal renal function, in patients with mild, moderate or
severe renal impairment, and in patients with end-stage renal disease on hemodialysis. An
additional objective of this study is to study the clearance of colchicine and its
metabolites by hemodialysis. Secondary objectives include evaluation of the safety and
tolerability of colchicine in the study population.
Clinical Details
Official title: Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Maximum Plasma Concentration (Cmax)Time to Maximum Plasma Concentration (Tmax) Area Under the Concentration Time Curve From Time Zero to the Time of Last Measured Concentration (AUC 0-t) Area Under the Concentration Time Curve From Time Zero to Infinity (AUC 0 - ∞) Apparent First-order Terminal Elimination Rate Constant (Kel) Apparent First-order Terminal Elimination Half-life (t½) The Apparent Total Volume of Distribution After Administration (V-area/F) Weight-adjusted Apparent Total Volume of Distribution After Administration (V-area/F) Apparent Total Body Clearance of Colchicine Weight-adjusted Apparent Total Body Clearance of Colchicine Amount of Colchicine Excreted in Urine (Ae[0-t]) Percentage of Colchicine Dose Excreted in Urine up to the Final Collection Time Renal Clearance of Colchicine (CLR) Dialysis Clearance of Colchicine (CLD) Percentage of Colchicine Dose Recovered in Dialysate
Detailed description:
40 male and female subjects will be enrolled in the study and stratified into one of five
groups based on their renal status as determined from creatinine clearance (CrCL) estimated
using the serum creatinine (sCR) and the Cockcroft-Gault and Modified Diet in Renal Disease
(MDRD) equations as follows: Treatment group 1 - healthy adults with normal renal function
(CrCL/eGFR> 90 mL/min); Treatment groups 2, 3 and 4 - patients with mild (CrCL/eGFR 60-89
mL/min), moderate (CrCL/eGFR 30 to 59 mL/min), and severe (CrCL/eGFR 15 to 29 mL/min) renal
impairment, respectively; and Treatment group 5 - subjects with end-stage renal disease
requiring hemodialysis. On study day 1, participants in Treatment Groups 1 to 4 will be
administered one colchicine 0. 6 mg tablet at 8 a. m. under standard fasting conditions.
Blood samples will be collected from all participants before dosing and both blood and urine
samples will be collected for 120 hours post-dose on a confined basis at times sufficient to
adequately define the pharmacokinetics of colchicine and its primary metabolites. There will
be two study periods for treatment group 5; Period 1 off dialysis and Period 2 on dialysis
with a 14 day washout period between the two study periods. On study day 1, participants in
treatment group 5 will be administered one colchicine 0. 6 mg tablet under standard fasting
conditions immediately following dialysis. Blood samples will be collected from all
participants before dosing and for up to 70 hours post-dose at times sufficient to
adequately determine the pharmacokinetics of colchicine and its primary metabolites. All
adverse events will be evaluated by the investigator and reported in the participant's case
report form.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult males and females 18-70 years old with a body mass index of <39 kg/m^2.
- Patients with normal renal function or mild renal impairment should be generally
healthy on the basis of medical history and physical exam.
- Patients with moderate to end stage renal impairment should be generally medically
healthy other than with respect to the morbidities associated with impaired renal
function.
- Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive
measures).
Exclusion Criteria:
- Known hypersensitivity to colchicine or any component of the formulation of the study
drug.
- Patients with a history or presence of a significant medical condition that would
interfere with interpretation of the study results.
- Patients who have used any drugs or substances known to inhibit or induce cytochrome
P450 (CYP) enzymes and/or P-glycoprotein within 28 days prior to the first dose and
throughout the study.
- Patients with recent (2 year) history or evidence of alcoholism or drug abuse or
significant psychiatric disease.
- Patients with chronic hepatic dysfunction.
Locations and Contacts
West Coast Clinical Trials, Cypress, California 90630, United States
Additional Information
Starting date: May 2010
Last updated: September 11, 2012
|